Vancouver, British Columbia – (Newsfile Corp. – November 29, 2021) – CVR Medical Corp. (TSXV: CVM) (OTC Rose: CRRVF) (“Medical CVR“or the”Society” Where “we“) a listed US-based Canadian healthcare company in the medical device market is pleased to announce the completion and filing of its second quarter 2021 financial statement. The financial report is posted on SEDAR .
About CVR Medical
CVR Medical Corp. is a healthcare company operating in the medical device industry focused on the commercialization of its proprietary and revolutionary Carotid Stenosis Analysis Device (the “CSSThe CSS is a diagnostic tool that encompasses the analysis technology of subsonic, infrasonic and low frequency sound waves. The CSS is a patented device designed to detect and measure carotid artery stenosis. CVR Medical are listed on the OTCQX under the symbol “CRRVF”. The Company was previously listed for trading under the symbol “CVM”. Additional information regarding the Company can be found in our recent filings with SEDAR as well as the information maintained on our website at www.cvrmed.com.
ON BEHALF OF THE BOARD:
(signed) Paul Blunden, MD
For more information contact:
Paul Blunden, MD, President / Director
Email: [email protected]
This press release contains forward-looking information which involves various risks and uncertainties regarding future events relating to: trading and dialogue with the Stock Exchange, communications and negotiations with CVR Global, dialogue with certain advisers, the Term Sheet, the Project of Restructuring, the Contract, the license agreement, the review, certain requirements in matters of company and securities law, the raising of capital, the 2019 audit and potential litigation. Such statements are subject to risks and uncertainties which may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of the future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will derive from them. These forward-looking statements reflect the current opinions of management and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by forward-looking statements, including: (1) a material setback or setback in negotiations between the Company and CVR Global ; (2) failure of the Company to resume trading on the Exchange; (3) a failure of the Company to raise sufficient capital to relaunch the Company; (4) an inability to enter into a definitive agreement with CVR Global; (5) a slowdown in general economic conditions in North America and internationally, (6) the inherent uncertainties and speculative nature associated with the commercialization of technology and the practice of medicine; (7) a change in health regulations; (8) any number of events or causes that may delay or stop the marketing and development of the CSS device; (9) the risk that the Company does not execute its business plan, (10) the risk of litigation between the Company and certain shareholders and the risk of litigation in general; (11) an inability to retain key employees, (12) an inability to fund operations and growth, (13) compliance with certain requirements of corporate and securities law; and (14) other factors beyond the control of the Company. These forward-looking statements are made as of the date of this press release and, except as required by law, the Company assumes no obligation to update these forward-looking statements or to update the reasons why actual results differ. of those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED OR REJECTED THE CONTENT OF THIS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATORY SERVICES PROVIDER (AS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS COMMUNICATION.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/105777